Antihyperlipidemic Effects of Oyster Mushrooms
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00069524 |
Recruitment Status
:
Completed
First Posted
: October 1, 2003
Last Update Posted
: September 26, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Hyperlipidemia | Drug: oyster mushroom | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 20 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Antihyperlipidemic Effects of Oyster Mushrooms |
Study Start Date : | June 2004 |
Actual Study Completion Date : | May 2006 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Documented HIV infection (positive ELISA and Western Blot or measurable plasma HIV RNA).
- Taking Kaletra (ritonavir/lopinavir), a ritonavir-containing antiretroviral therapy, for at least 12 weeks
- Elevated non-HDL cholesterol >= 160 mg/dl as defined by the National Cholesterol Education Program guidelines (within 30 days of enrollment)
- AST or ALT <2.5 times the upper limit of normal (ULN) within 30 days of study entry.
Exclusion criteria:
- Currently receiving antihyperlipidemic treatment (e.g., statins, fibrates, bile sequestrants, niacin)
- Pregnancy or breastfeeding
- Documented history of myopathy or myalgias on HMG-CoA reductase inhibitors
- Documented history of rhabdomyolysis
- Documented diagnosis of diabetes mellitus
- Any condition that, in the judgment of the investigator, precludes successful participation in the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00069524
United States, California | |
General Clinical Research Center, San Francisco General Hospital | |
San Francisco, California, United States |
Principal Investigator: | Donald I Abrams, MD | University of California, San Francisco |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00069524 History of Changes |
Other Study ID Numbers: |
R21AT001782-01 ( U.S. NIH Grant/Contract ) |
First Posted: | October 1, 2003 Key Record Dates |
Last Update Posted: | September 26, 2007 |
Last Verified: | September 2007 |
Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
Highly active antiretroviral therapy (HAART) Ritonavir Oyster mushrooms |
Non-HDL cholesterol Complementary Therapies Treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Hyperlipidemias Hyperlipoproteinemias Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |